Rasko Nathalie B, Nahm Christopher B, Turchini John, Teh Rachel, Rasmussen Helge, Byeon Sooin, Sahni Sumit, Samra Jaswinder S, Gill Anthony J, Mittal Anubhav
Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Upper Gastrointestinal Surgical Unit, Department of Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Cancer Med. 2025 Jan;14(1):e70500. doi: 10.1002/cam4.70500.
FXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993-2014).
FXYD3 expression was assessed in tumour specimens using immunohistochemistry.
145 of 180 PDAC tumour specimens were FXYD3-immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log-rank p = 0.9718). FXYD3 expression correlated positively with late-stage disease (OR 3.041, 95% CI 1.190-7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade.
Immunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.
FXYD3是一种钠钾ATP酶调节剂，在胰腺导管腺癌（PDAC）中上调，但其预后作用尚不清楚。本研究评估了单一中心（1993 - 2014年）接受手术切除的未经化疗的PDAC患者中FXYD3的表达情况。
采用免疫组织化学方法评估肿瘤标本中FXYD3的表达。
180例PDAC肿瘤标本中有145例FXYD3免疫阳性（80.5%）。FXYD3阴性组（27.60个月）和阳性组（25.00个月）的中位总生存期无差异（对数秩检验p = 0.9718）。FXYD3表达与晚期疾病呈正相关（优势比3.041，95%可信区间1.190 - 7.455，p = 0.0175）。与T分期、阳性淋巴结、神经周围浸润、淋巴管浸润或组织学分级无显著关联。
免疫组织化学检测FXYD3表达不能预测未经化疗的PDAC患者的生存情况，但与晚期疾病相关。FXYD3的高过表达率值得进行治疗评估。
